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Abstract: Background: Molecular mechanism of differentiation in lipogenic tumor is still unknown in detail. Low-density 
lipoprotein receptor-related protein (LRP) and peroxisome proliferator-activated receptor gamma (PPAR-), 
representative regulatory molecules of lipogenic differentiation, have been reported today as multi-functional molecules 
and to modulate tumorigenesis in various kind of cancer. To date, diagnostic and therapeutic significance of the 
expression of these molecules in lipogenic tumors are not defined. 
Methods: The immunohistochemical expression status of LRP and PPAR- in various grades of 54 lipogenic tumors was 
analyzed. Correlation between the expression levels and the differentiation of the tumors was confirmed. For statistical 
analyses, the Kruskal-Wallis test, the Steel-Dwass test and the Mann–Whitney U test were used. 
Results: LRP and PPAR- expression was detected in 50 (92.6%) and 44 (81.5%) cases, respectively. The expression level 
in LRP was significantly higher in cases with well differentiated liposarcoma, pleomorphic liposarcoma and 
dedifferentiated liposarcoma than in lipoma. Compared with lipoma or well differentiated liposarcoma, significant 
elevation in expression level of PPAR- was confirmed in myxoid liposarcoma, pleomorphic liposarcoma, 
dedifferentiated liposarcoma and the differentiated area of dedifferentiated liposarcoma. 
Conclusion: The up-regulation of LRP and PPAR- in higher grade cases, i.e. less differentiated tumors than in low grade 
cases was shown, suggesting the candidate role of these molecules as tumor progression modulators rather than regulatory 
molecules of differentiation in lipogenic tumors. 
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INTRODUCTION 
  Low-density lipoprotein receptor-related protein (LRP) is 
a cell surface receptor that is frequently found in the liver, 
placenta, brain, epithelial cells of the digestive system, 
smooth muscle cells, macrophages and fibroblasts [1-3]. 
LRP is a member of the low-density lipoprotein receptor 
(LDLR) family, which comprises LRP, LDLR, very low-
density lipoprotein receptor and other several molecules [4]. 
When LRP was originally identified, the structural 
similarities to LDLR and expression in the liver suggested a 
role in lipoprotein metabolism and cholesterol homeostasis. 
Further in vitro evidence that LRP binds apolipoprotein E 
(apo E) led to the proposal that this molecule serves as a 
receptor for chylomicron remnants, lipoproteins that 
primarily shuttle dietary cholesterol from the gut to the liver. 
However, considerable evidence began to emerge suggesting  
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that a major function of LRP lies in the removal of proteinase 
and proteinase inhibitor complexes, raising the possibility that 
this molecule acts as a multifunctional scavenger receptor [4]. 
To date, LRP has been reported to bind and endocytose over 
30 structurally and functionally distinct ligands, including 
proteinases such as matrix metalloproteinases (MMPs) and 
urokinase-type plasminogen activator (uPA) [4]. The 
importance of these proteolytic enzymes in tumor progression 
suggests a critical role for this molecule in malignancy. In fact, 
LRP expression has been reported in various kinds of tumors, 
including astrocytoma, colon cancer, renal cancer and 
melanocytic tumor [5-8]. However, the precise roles and 
potential underlying mechanisms for this molecule in 
malignancy remain controversial. 
  Peroxisome proliferator-activated receptors (PPARs) are 
members of a super family of nuclear receptors. The PPAR 
subfamily has three isotypes: , /, and , which are ligand-
activated transcription regulators that are important in cellular 
homeostasis [9]. Among these, PPAR- is a nuclear hormone 
receptor that plays a critical role in adipocyte differentiation and 
control of lipid uptake [10]. The molecule is expressed in 
preadipocytes at limited levels and is turned on during Significance of LRP and PPAR- Expression in Lipomatous Soft Tissue Tumors  The Open Orthopaedics Journal, 2010, Volume 4    49 
differentiation, prior to the expression of most adipocyte genes, 
many of which contain PPAR-binding sites [11]. Expression of 
this molecule in malignancy, induction of differentiation by 
ligands of this molecule in cancer cells, and growth inhibition of 
tumor by specific ligands all imply roles for PPAR- in 
tumorigenesis [12-14]. A recent in vitro study of a liposarcoma 
cell line found that expression levels of LRP were regulated by 
PPAR- [15]. 
  Common properties of these two molecules such as close 
relationships with tumorigenesis and regulatory effects on fat 
metabolism or lipogenic differentiation strongly suggest that 
these molecules probably act as key players of regulation in 
the cell function of lipogenic tumors. However, limited data 
has been available regarding the expression status of these 
molecules in lipogenic tumors [10, 16]. Liposarcoma is one 
of the most frequent soft tissue sarcomas in adults, and has 
usually been divided into four major categories classically 
based on histological findings: well-differentiated 
liposarcoma (WDLS); dedifferentiated liposarcoma (DDLS); 
myxoid/round cell liposarcoma (M/RLS); and pleomorphic 
liposarcoma (PLLS). As with other numerous malignancies, 
intensity of differentiation is believed to regulate histological 
grade and prognosis. Recent fruits of genetic analysis depict 
the profound molecular mechanisms affecting morphology in 
lipomatous tumors. Recent reports have shown close 
relationships between WDLS and 12q13-15 region 
amplification, between DDLS and 1p32 or 6q23 
amplification, and between M/RLS and the t(12;16) 
translocation [17, 18]. Despite these intensive analyses, 
details of molecular events in the common regulatory 
mechanism of lipogenic differentiation are still unknown. 
We examined herein the expression of LRP and PPAR- in 
lipogenic tumors, including lipoma and various grades of 
liposarcoma in order to seek the fundamental, diagnostic and 
therapeutic significance of the expression of these two 
molecules under the hypothesis that these molecules play a 
critical role in the regulation of lipogenic tumor malignancy 
and differentiation. 
MATERIALS AND METHODS 
  Specimens were obtained from 54 patients who had 
undergone surgical resection or open biopsy at the registered 
institutes. Histological diagnosis was confirmed by standard 
light-microscopic evaluation of sections stained with 
hematoxylin and eosin by two authors (Y.F. and F.K.). 
Classification of tumors used in this study was based on the 
revised World Hearth Organization (WHO) criteria for soft 
tissue tumors with minor modification [19]. Tumors that did 
not contain round cell components throughout the specimen 
were independently myxoid liposarcoma (MLS) among the 
tumors diagnosed as M/RLS. Cases that needed subtle 
differential diagnosis such as lipoma and WDLS were 
subjected to chromosomal analysis. Finally, specimens were 
diagnosed as lipoma in 15 cases, WDLS in 12 cases, MLS in 
11 cases, M/RLS in 5 cases, PLLS in 6 cases and DDLS in 5 
cases. Immunohistochemical studies were performed using 
the dextran polymer method (EnVision
TM/HRP; DAKO 
Japan, Tokyo Japan). For immunohistochemistry, 5-μm thick 
paraffin sections were placed onto silane-coated glass slides. 
After deparaffinization in xylene, antigen activation was 
performed by autoclaving for 20 min (121°C). Nonspecific 
antibody binding was blocked using a specific blocking 
reagent (0.03% H2O2, sodium azide) for 10 min at room 
temperature. Sections were incubated with mouse 
monoclonal antibody against LRP (Clone 5A6 mouse 
monoclonal immunoglobulin; PROGEN, Toowong, 
Australia) and against PPAR- (Clone 6E3-F1 mouse 
monoclonal immunoglobulin; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) overnight at 4°C. At incubation, 
primary antibodies were diluted in 1:200 (LRP) and 1:50   
(PPAR-) in Tris-buffered saline (TBS) (DAKO Japan). 
Negative controls were performed by substituting normal 
mouse serum for primary antibodies. As controls for positive 
LRP and PPAR-  staining, human liver tissue and human 
breast carcinoma tissue were used, respectively [4, 20, 21]. 
After washing in TBS, sections were incubated with polymer 
reagent (Labeled Polymer HRP; DAKO Japan) for 30 min at 
room temperature. The complex was visualized using 3,3’-
diaminobenzidinetetrahydrochloride (DAB) (DAKO Japan). 
Sections were counterstained with hematoxylin. We selected 
5 most-typical sections in each case. If the samples of cases 
did not have enough volume for making 5 sections, all 
sections were evaluated. Immunohistochemical staining for 
antigens was evaluated using a modified method of Nawa et 
al. [10, 22]. In brief, tumor cells showing a definite staining 
pattern were scored as positive, regardless of staining 
intensity. Areas containing the largest number of positive 
cells were selected and numbers of positive cells per 600 
tumor cells were counted. Percentages of positive cells were 
calculated as the positive rate. If the number of cells failed to 
reach 600, the number of positive cells as a percentage of the 
total countable tumor cells was calculated as the positive 
rate. For dedifferentiated cases, the well-differentiated area 
and dedifferentiated area were evaluated separately. For 
statistical analyses, the Kruskal-Wallis test, Steel-Dwass test 
and Mann-Whitney U test were used. Values of P<0.05 were 
considered significant. All patients were informed that the 
surgical specimen would be subject to this study, and 
provided written form consent. 
  This study was approved by the institutional ethics 
committees, and informed consent was obtained from each 
patient. 
RESULTS 
  Using a monoclonal antibody directed against the LRP, we 
found LRP in the lipomatous tumor of 50 patients (92.6%) 
(Fig. 1). No immunostaining was observed after the omission 
of primary antibody (data not shown). Significant differences 
in LRP were confirmed among 7 groups. The positive rate was 
significantly higher in WDLS, PLLS and DDLS than in 
lipoma. No significant differences were identified between 
WDLS and the area of WDLS in DDLS (Fig. 2). 
  We found PPAR- in the lipomatous tumor of 44 patients 
(81.5%) (Fig. 3). No immunostaining was observed after 
omission of the primary antibody (data not shown). 
  Significant differences in PPAR- expression were seen 
among 7 groups (Fig. 4). No significant difference in 
expression level was apparent between lipoma and WDLS. 
Compared with the expression rate in lipoma or WDLS, a 
significant elevation in positive rate was confirmed in MLS, 
M/RLS, PLLS, DDLS and the area of WDLS in DDLS. 
Interestingly, a considerably high expression rate was 
confirmed in both DDLS and the area of WDLS in DDLS. 50    The Open Orthopaedics Journal, 2010, Volume 4  Tajima et al. 
 
 
Fig. (1). Immunohistochemical expression of LRP in lipoma (b), WDLS (d), M/RLS (f), PLLS (h), DDLS (j) and DDLS-WDLS (l). 
Negative control (normal mouse serum) of each sections (a, c, e, g, i, k). Original magnification 400. Positive expression was seen in 50 
patients (92.6%). Significance of LRP and PPAR- Expression in Lipomatous Soft Tissue Tumors  The Open Orthopaedics Journal, 2010, Volume 4    51 
  Correlations of expression rates between these two 
molecules were also analyzed, confirming a significant 
correlation between the two molecules (p = 0.004) (Fig. 5). 
DISCUSSION 
  The present study has shown the up-regulation of LRP 
and PPAR-, both of which are believed to be critical 
regulatory molecules of lipogenic differentiation, in high-
grade, i.e., less-differentiated lipogenic tumors, than in low-
grade tumors. 
  The regulatory function of LRP on tumor was identified 
on the basis of the following; distinct expression in various 
malignant tumor; ligation with MMP or uPA, which are 
critical for tumor invasion [4-8]. However, the actual role of 
this molecule in malignancy, i.e., whether inhibitory or 
progressive, remains controversial due to variations in the 
relationship between expression level and tumor grade [6, 7, 
8, 23]. The origin of such controversial aspects is, at least 
partly, thought to arise from the multi-functional properties 
of this molecule [22, 24].  Variety of parameters might 
change the role of this molecule in regulating tumor activity, 
resulting in controversial aspects of the properties of the 
molecule. In the interpretation of the molecular expression in 
lipogenic tumor, multifactorial functions of the molecule 
both in terms of fat metabolism and differentiation and of 
regulatory activity of tumor should have been considered. 
We first planned this study under the hypothesis that the 
molecule could regulate fat differentiation in lipogenic 
tumor, i.e. higher expression in low-grade or benign cases. 
However, the results revealed an inverse trend. LRP might 
thus act as a tumor progression regulator rather than in the 
differentiation of the fat lineage in the system. Previously, 
up-regulation of uPA expression has been noted in the 
invasive front or cases of myxoid liposarcoma with worse 
prognosis (Morii T, et al. unpublished data in English 
literature), suggesting a close relationship between LRP and 
tumor progression. 
  A recent report has suggested a regulatory function of 
PPAR- ligands for LRP expression [15]. Interestingly, a 
significant relationship between expression rates was 
identified between these two molecules in the present study, 
supporting the above-mentioned hypothesis. Further 
systemic analysis of the proteolysis-internalization system 
comprising LRP and related proteolytic enzymes, together 
with PPAR- function in regulating LRP in terms of both 
tumor activity and fat differentiation, should be performed in 
the future. 
  Overexpression of PPAR- in high-grade cases or 
malignancy has been reported [25-28]. In vitro analyses 
showing that antagonism of this molecule results in cell 
growth inhibition support these results [13, 25]. In contrast, 
other reports have found PPAR- to be expressed more often 
in cases showing low grade or better prognosis, rather than 
in those with high grade or poor prognosis [20, 29]. In the 
present study, expression of PPAR-  was shown to be 
elevated according to the malignancy of the lipogenic tumor. 
A previous report has confirmed the expression and up-
regulation of m-RNA of this molecule in lipogeneic tumor 
[10]. However, that report did not show the relationship of 
expression intensity and tumor grade or differentiation, 
perhaps because of a smaller number of cases, unlike the 
present study. Up-regulation of this molecule in high-grade 
and less-differentiated cases has evoked several enigmas as 
to the function of this molecule in lipogenic tumor, because 
this molecule was, at least originally, believed to have a 
regulatory function in fat differentiation. As with LRP, we 
initially hypothesized that down-regulation might be 
confirmed in less-differentiated cases. 
 
 
 
Fig. (2). Average LRP-positive rate. Results are shown as means and standard deviation (SD). DDLS-WDLS: Area of WDLS in 
dedifferentiated liposarcoma. * P<0.05. The positive rate was significantly higher in WDLS, PLLS and DDLS than in lipoma.  52    The Open Orthopaedics Journal, 2010, Volume 4  Tajima et al. 
   
 
 
Fig. (3). Immunohistochemical expression of PPAR- in lipoma (b), WDLS (d), M/RLS (f), PLLS (h), DDLS (j) and DDLS-WDLS (l). 
Negative control (normal mouse serum) of each sections (a, c, e, g, i, k). Original magnification 400. The positive expression was seen in 
44 patients (81.5%). Significance of LRP and PPAR- Expression in Lipomatous Soft Tissue Tumors  The Open Orthopaedics Journal, 2010, Volume 4    53 
 
 
Fig. (4). Average PPAR--positive rate. Results are shown as mean and standard deviation (SD). DDLS-WDLS: Area of WDLS in 
dedifferentiated liposarcoma. * P<0.05: Positive rate was significantly higher in MLS, PLLS, DDLS and WDLS in DDLS than in lipoma.  
# P<0.05: Positive rate was significantly higher in MLS, M/RLS, PLLS, DDLS and WDLS in DDLS than in WDLS. 
 
Fig. (5). Correlation of expression rate between LRP and PPAR- (p=0.004, R
2=0.135). 54    The Open Orthopaedics Journal, 2010, Volume 4  Tajima et al. 
 PPAR- also has multiple functions, including acting as a 
promoter of lipogenesis, inflammation regulator and 
tumorigenesis promoter. PPAR- ligands such as 
troglitazone induce growth arrest not only in macrophages 
and endothelial cells, but also in several cancer cells such as 
prostate and breast cancer cells both in vitro and in vivo [30, 
31]. Where expression is elevated in low-grade cases, some 
authors have attributed the phenomenon to activation of the 
ligand-receptor system that suppresses tumor activity [20]. 
This hypothesis seems plausible, but most reports of PPAR- 
expression in malignancy have revealed the converse, 
supporting the results of the present study. Although the 
precise reasons for this discrepancy are difficult to clarify, 
some authors have speculated that considering the diversity 
of human cancer, expression of PPAR- may be dependent 
on tissue specificity and/or the mutational events requisite 
for cancer development [26, 32]. 
  Although still under debate in some aspects, the role of 
PPAR- in tumor growth inhibition has been extensively 
studied in terms of experimental, clinical and etiological 
aspects during the last several years. Many experimental 
model studies have demonstrated that PPAR- ligands are 
anti-tumorigenic due to anti-proliferative, pro-differentiation 
and anti-angiogenic effects [13, 25, 33-35]. Moreover, 
etiological analysis on a database from ten Veteran Affairs 
medical centers in the United States revealed a strong 
association between the use of pioglitazone and reduced risk 
of lung cancer [36]. 
  The present data suggested the possibility of clinical 
application of these immunohistochemical methods as strong 
tool for the evaluation of malignancy in lipogenic tumors. 
Tumors with high expression of PPAR- can thus be 
candidates for molecular targeted therapy through the 
application of PPAR- ligands that can suppress 
tumorigenesis or tumor proliferation. In fact, a recent clinical 
trial showed the probability of this receptor as a target of 
tumor suppression in liposarcoma [10, 37], suggesting tumor 
suppression in patients with intermediate/high-grade 
liposarcoma through the induction of differentiation by the 
PPAR- ligand. The subject in the present study was 
consistent with the largest range of lipomatous tumors and 
showed a broad range of considerably higher expression for 
this receptor in high-grade cases than in low-grade or benign 
cases, supporting the potential of this approach as a 
promising and attractive strategy. 
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